The Europe Swine Vaccines Market comprises veterinary biological preparations specifically engineered to stimulate active immune responses or provide passive maternal immunity in swine against infectious viral and bacterial pathogens across the EU-27 Member States and the United Kingdom. In strict compliance with Regulation (EU) 2019/6 on Veterinary Medicinal Products (EU VMP) and European Medicines Agency (EMA) CVMP guidelines, the market scope includes commercial prophylactic biologicals (inactivated/killed bacterins and viral vaccines, modified live attenuated vaccines, recombinant subunit constructs, and viral-vectored platforms) as well as custom herd-specific autogenous vaccines manufactured under Article 106 derogations. The market strictly excludes swine therapeutics (antibiotics, parasiticides, NSAIDs), direct-fed microbials, nutritional feed additives, diagnostic assay kits, and biologicals formulated for non-swine livestock or companion animals.
The Europe Swine Vaccines Market is estimated at USD 535.50 million in 2025, registering a CAGR of 4.80% during the forecast period. Growth is driven by regional biopharmaceutical premiumization, expanding adoption of needle-free intradermal delivery platforms, and strict European regulatory restrictions on prophylactic antibiotics.
The market is experiencing strong structural growth in high-value multivalent and enteric segments. For instance, as per the European Food Safety Authority (EFSA) 2025 Epidemiological Audits, endemic PRRS and PCV2d viral challenges cause European herd losses of EURO 126 to EURO 350 per sow annually, driving commercial active immunization rates to 95.0% for PCV2 and 72.0% for PRRS across Western European production hubs.
Europe Swine Vaccines market report is based on a robust research methodology designed using a blend of research ap-proaches developed using secondary/desk research and validated through primary research and expert insights. Eternity Insights also uses paid databases such as FACIVA, Hoovers, and other benchmarking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
The Europe Swine Vaccines market is estimated to expand at a considerable growth rate during the forecast period owing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, key market players are investing in research and development of technologically advanced products, leading to increased utilization of Europe Swine Vaccines products across developed and developing countries worldwide.
Limited awareness about the diseases, high cost of products, low economic conditions, and lack of favorable insurance systems restrict the adoption of Europe Swine Vaccines products across developing regions of the globe. However, the launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Europe Swine Vaccines market.
To learn more about this report
Increasing research and development spending on Europe Swine Vaccines development has been the leading industry trend of Europe Swine Vaccines market
The leading players in the market are focused on developing products which are cost-effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be witnessed from the increasing spending on research and development and growing number of new product approvals.
To learn more about this report
| Report Attributes | Details |
| The market size value in 2025 | USD XX.XX Million |
| CAGR (2026 - 2035) | XX.XX % |
| The Revenue forecast in 2035 | USD XX.XX Million |
| Base year for estimation | 2025 |
| Historical data | 2021-2024 |
| Forecast period | 2026-2035 |
| Quantitative units |
|
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | By Technology Architecture Outlook, Delivery Platform Outlook, Regional Outlook |
| By Technology Architecture Outlook | Inactivated / Killed Vaccines, Live Attenuated Vaccines (LAV / MLV), Recombinant & Subunit Vaccines, Autogenous / Custom Swine Vaccines, Emerging / Next-Gen Platforms (Exploratory) |
| By Delivery Platform Outlook | Traditional Injectable (IM / SC), Needle-Free / Intradermal (ID) Delivery Platforms, Oral / Water-Administered Vaccines, Other |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope | U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled | Boehringer Ingelheim Animal Health, Zoetis Inc., MSD Animal Health (Merck & Co.), Ceva Santé Animale, Hipra SA, Virbac, Huvepharma, Vetoquinol, Elanco |
| Customization Available | Yes, we can tailor the report to your specific requirements. |
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
A faster and efficient way to cater to the needs with continuous iteration
Focus on Data Accuracy & Reliability
75+ Clients in Fortune 500
All your transactions are secured end-to-end, ensuring a satisfactory purchase
Ensure the best and affordable pricing
